Core Viewpoint - Xishan Technology (688576.SH) is facing significant challenges with declining revenue and profits, prompting investor concerns and discussions about the company's future strategies and stock buyback practices [1][2][3] Group 1: Company Overview - Xishan Technology, headquartered in Chongqing, specializes in surgical power devices, endoscopic systems, and energy surgical equipment, serving various clinical departments [1] - The company went public on the Shanghai Stock Exchange's Sci-Tech Innovation Board on June 6, 2023, with a strategic placement of shares [1] Group 2: Financial Performance - In 2024, Xishan Technology reported a revenue of 336 million yuan, a year-on-year decrease of 6.74%, and a net profit of 71.71 million yuan, down 22.45% [1] - For Q1 2025, the company generated revenue of 65.88 million yuan, a decline of 11.2% year-on-year, and a net profit of 8.99 million yuan, down 55.02% [2] Group 3: Investor Concerns - Investors have expressed concerns regarding the company's continuous revenue decline and significant profit drops since its IPO, questioning the effectiveness of the company's strategies to reverse this trend [2][3] - Xishan Technology has conducted multiple share buybacks, totaling approximately 490 million yuan, which has not positively impacted the stock price, leading to further investor dissatisfaction [3] Group 4: Stock Performance - As of June 9, 2025, Xishan Technology's stock price was 64.55 yuan per share, representing a decline of about 52.4% from its initial offering price of 135.80 yuan [3]

# 关于西山科技 重庆西山科技股份有限公司成立于 1999 年 12 月，2023 年 6 月在科创板上市，是一家 集数字化微创外科手术设备及耗材的研发、制造、销售、服务于一体 的国家高新技术企业。 报名：首届全球心血管大会 | 最新议程 合作伙伴征集：2025全球手术机器人大会 2025年4月29日， 西山科技 发布2024年年报。 # 财务数据 产品与业务 营业收入与利润 ： 2024 年实现营业收入 3.36 亿 元，同比下降 6.74% ； 归母净利润 9866.69 万元，同比下降 15.92%；扣非后净利润 7171.03 万元，同比下降 22.45%。 资产负债率与每股收益 ： 资产负债率为 8.35% ，较去年同期增加 1.56 个百分点； 摊薄每股收益为 1.97 元，较去年 同报告期下降 22.13%。 经营活动现金流 ： 经营活动现金净流入为 3946.89 万 元，同比下降 42.03%， 主要原因是本期材料采购、职工薪 酬、税金和研发费用开支较上期增多。 手术动力装置 ：覆盖 神经外科、耳鼻喉科、骨科、乳腺外科等临床科室， 拥有多样产品型号规格，能满足各科室绝大 部分手术需求。 内窥 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is experiencing short-term pressure but is expected to improve gradually quarter by quarter [1] - In 2024, the company achieved total revenue of 36.726 billion yuan, a year-on-year increase of 5.14%, and a net profit attributable to shareholders of 11.668 billion yuan, a year-on-year increase of 0.74% [7] - The company anticipates a turning point in 2025, despite short-term challenges in the domestic market [7] Financial Performance Summary - Total revenue projections for the company are as follows: 39.369 billion yuan in 2025, 45.061 billion yuan in 2026, and 52.403 billion yuan in 2027, with respective year-on-year growth rates of 7.20%, 14.46%, and 16.29% [1] - Net profit attributable to shareholders is projected to be 11.960 billion yuan in 2025, 13.131 billion yuan in 2026, and 15.280 billion yuan in 2027, with year-on-year growth rates of 2.50%, 9.79%, and 16.37% [1] - The latest diluted EPS is expected to be 9.86 yuan in 2025, 10.83 yuan in 2026, and 12.60 yuan in 2027 [1] Business Segment Performance - The Life Information and Support business generated revenue of 13.557 billion yuan in 2024, a decrease of 11.11% year-on-year, while the International Life Information and Support business saw double-digit growth [7] - The In Vitro Diagnostics (IVD) business achieved revenue of 13.765 billion yuan, a year-on-year increase of 10.82%, marking its first time exceeding the Life Information and Support business in revenue [7] - The Medical Imaging segment generated revenue of 7.498 billion yuan, with international business growth exceeding 15% [7] - The Electrophysiology and Vascular Intervention segment generated revenue of 1.439 billion yuan, with the acquisition of control over Huitai Medical to enhance cardiovascular segment capabilities [7] Innovation and Growth Drivers - The company launched several innovative products in 2024, including advanced medical systems and AI-driven solutions to improve patient care and operational efficiency [7] - The company maintains a strong competitive position due to its diverse product lines and continuous innovation [7]

Financial Performance - In 2024, the company achieved total revenue of 36.726 billion CNY, a year-on-year increase of 5.14% [2] - The net profit attributable to shareholders was 11.668 billion CNY, up 0.74% year-on-year; excluding financial expenses, the net profit growth was 4.36% [2] - Operating cash flow reached 12.432 billion CNY, reflecting a year-on-year increase of 12.38% [2] - For Q1 2025, total revenue was 8.237 billion CNY, a decline of 12.12% compared to the same period last year, with net profit down 16.81% [9] Dividend Distribution - The company plans to distribute 679 million CNY (including tax) as dividends for 2024, with a cumulative cash dividend of 7.602 billion CNY, representing a payout ratio of 65.15% [3] - A proposal for a mid-year dividend of 1.71 billion CNY (including tax) for 2025 is also in place, pending shareholder approval [3] Market Performance International Market - The international market grew by 21.28% in 2024, with the Asia-Pacific region seeing nearly 40% growth driven by countries like Australia, Thailand, and India [4] - International revenue accounted for approximately 45% of total revenue, with high-potential segments like minimally invasive surgery and cardiovascular care nearing 10% of international income [4] Domestic Market - The domestic market experienced a decline of 5.10% due to sluggish hospital equipment procurement and the impact of DRG 2.0 [4] - A recovery is anticipated in Q3 2025 as local fiscal pressures ease and medical equipment projects are initiated [4] Product Line Performance In Vitro Diagnostics (IVD) - The IVD segment grew by 10.82% in 2024, with international IVD growth exceeding 30% [5] - IVD revenue now constitutes 37.48% of total company revenue, surpassing the life information and support segment [5] Medical Imaging - The medical imaging segment grew by 6.60%, with international growth over 15% [7] - The launch of the high-end Resona A20 ultrasound is expected to enhance market presence [7] Life Information and Support - This segment saw a decline of 11.11%, although international growth was in double digits [8] - The company maintains a leading market share in domestic monitoring and respiratory devices despite challenges [8] Research and Development - R&D investment for 2024 was 4.008 billion CNY, accounting for 10.91% of revenue, while Q1 2025 saw 847 million CNY in R&D, representing 10.28% of revenue [11] - New product launches include advanced systems in life information and support, IVD, and medical imaging [12][13] Sustainability Efforts - The company received an AA rating from MSCI ESG and was included in the S&P Global Sustainable Development Yearbook [14] - Carbon emissions intensity decreased by 11.6% compared to 2021, with ongoing projects contributing to sustainability goals [15] Future Outlook - The company anticipates a significant recovery in domestic revenue starting Q3 2025, driven by the resumption of medical equipment projects [10] - Long-term growth strategies focus on digitalization, internationalization, and enhancing the supply chain to adapt to changing market conditions [24][25]

报名：首届全球眼科大会 | 议程更新 那么，本次 医学影像展区 都将展出哪些创新产品呢？一起来看看吧！ # GE医疗 展位 ：3R13 展品 ： "英雄"磁共振结合"Sonic深度学习平台" GE医疗 是一家全球领先的医疗科技、诊断药物和数字化解决方案的创新企业，致力于通过整合解决方案和服 务提升医疗效率和精准度。公司业务遍及 160多个国家和地区 ，年营收超196亿美元，拥有全球员工51,000 名。 GE医疗的 SIGNA Hero磁共振设备通过搭载人工智能深度学习Sonic平台 ，实现了"脑心同治"理念的落地。该 设备将传统超过一小时的检查时间缩短至半小时，仅需一次造影剂注射即可完成脑心联合评估，大幅提升检查 效率和成功率。此外，SIGNA Hero还具备 高分辨斑块成像功能 ，能够评估缺血性脑卒中和心脏病风险，为不 明原因卒中患者提供全面诊断信息。 基于SIGNA Hero的脑心同治及肿瘤精准诊疗应用方案已入选《2024年高端医疗装备推广应用项目》，并由天 津医科大学总医院牵头，联合多家医院进行临床应用研究。 # 飞利浦医疗 报名：首届全球骨科大会 | 议程更新 报名：首届全球心血管大会 | 奖项申报 ...

报名：首届全球眼科大会 | 议程更新 报名：首届全球骨科大会 | 议程更新 报名：首届全球心血管大会 | 奖项申报 合作伙伴征集：2025全球手术机器人大会 近日， 杭州灵眸医疗科技有限公司 （ 简称"灵眸医疗"）宣布完成数千万人民币A轮融资。本轮由 九合创投 领投， 承树风华 跟投，老股东 海邦沣华 追加投资， 跃为资本 担任本轮独家财务顾问。 本轮融资主要用于加速公司 软镜系统国内外商业化进展和学术推广工作 ，并进一步 强化补充公司的内镜产品组合 ，以打造国产第一梯队的软性内窥镜品牌。 # 产品与技术 灵眸医疗的核心产品是 Alioth系列电子内窥镜系统 ，该产品于2024年5月正式获得国家药品监督管理局（NMPA）批准。 系统采用全电传输技术，显著增强了临 床稳定性能，并提出 "全场景成像"理念 ，涵盖 HLI、SVI、TCI、DHI 四种特殊光成像模式，全面覆盖从检查到治疗的复杂成像需求。 以下是该产品的关键特点和 优势： 全电传输技术 全场景成像技术 创新功能 灵眸医疗于2021年于杭州成立，并同步建立深圳研发中心和杭州制造基地。创始团队由具备多年（平均10年）医疗器械从业经验的国内外资深工程师、专 ...

科创板投资风险提示 本次发行股票拟在科创板市场上市，科创板公司具有研发投入大、经营风险 高、业绩不稳定、退市风险高等特点，投资者面临较大的市场风险。投资者 应充分了解科创板的投资风险及本公司所披露的风险因素，审慎作出投资决 重庆西山科技股份有限公司 Chongqing Xishan Science&Technology Co.,ltd. （重庆市北部新区高新园木星科技发展中心（黄山大道中段 9 号）） 首次公开发行股票并在科创板上市 保荐机构（主承销商） （上海市黄浦区中山南路 318 号 24 层） 重庆西山科技股份有限公司 招股说明书（注册稿） 1-1-0 招股说明书 （注册稿） 定。 重庆西山科技股份有限公司 招股说明书（注册稿） 重要声明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对注册 申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行 人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任何与之 相反的声明均属虚假不实陈述。 目 录 | 重要声明 … | | --- | | 发行概况 … | | 日 求 … | | 第一节 释义 . | | 一、普通 ...